Novel Advances in Hereditary ATTR Amyloidosis: Payer and Specialty Pharmacy Considerations

Date:               Tuesday, April 30, 2019

Location:         Wynn and Encore Hotels
3131 S Las Vegas Boulevard
Las Vegas, Nevada 89109

Time:               7:00 am – 8:30 am
                        *Breakfast will be available

Program Description
Amyloidosis refers to a heterogenous group of multisystemic, debilitating, fatal disorders affecting normal tissue and organ structure and function due to amyloid fibril deposits in extracellular tissues. Hereditary transthyretin amyloidosis (hATTR) is one of these disorders and it affects approximately 50,000 individuals worldwide. As the disease progresses, patients experience a myriad of symptoms that may include weight loss, gastrointestinal dysfunction, and polyneuropathy. The course of hATTR may be slowed with early diagnosis and treatment. Until recently, treatments have only helped to alleviate symptoms, but the treatment landscape has changed in the United States with the approval of 2 disease-modifying therapies that target the disease process at the cellular level. Due to its progressive nature, hATTR impacts patients and their caregivers, both of whom report a much-reduced quality of life due to the physical, mental, and financial demands of the disease. Specialty pharmacists and payers must be familiar with current and emerging therapies for the treatment of hATTR to improve the clinical outcomes for patients with hATTR while managing health care resources.

Educational Objectives
  • Examine the pathophysiology of hereditary transthyretin amyloidosis (hATTR)
  • Explain the diagnostic challenges of hATTR
  • Analyze data supporting the use of current and emerging therapies for the treatment of hATTR
  • Identify approaches for payers to effectively manage ultra-rare diseases

Faculty Presenters
Karen Thomas, PharmD, PhD, DABAT
Pharmacy Supervisor, Specialty Pharmacy Services
University of Utah Health
Salt Lake City, Utah

Sami Khella, MD

This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-19-055-L01-P. The activity is available for CE credit for April 30, 2019.

Obtaining Credit:
All participants who attended the live symposium need to log on to their Pharmacy Times Continuing Education™ account on to complete an online evaluation form and request their credit. Detailed instructions on obtaining credit will be provided at the session. Credit must be requested no later than June 30, 2019.